NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.
- Two poster presentations reinforce the safety of MF59®-adjuvanted seasonal trivalent influenza vaccine in adults 65 years of age and older in addition to demonstrating increased breadth of antibody responses[1,2]
- Quadrivalent inactivated influenza vaccine data demonstrates safety and immunogenicity in children aged 5 to 17 and adults aged 18 years and older[3,4]
- Total of seven poster presentations and a symposium underscore Seqirus' commitment to prevention and control of seasonal influenza
MAIDENHEAD, United Kingdom, Aug. 24, 2016 /PRNewswire/ -- Seqirus announced today that seven poster presentations reporting results of the company's research and development in seasonal influenza prevention and control have been accepted at the Options IX for the Control of Influenza conference (Options IX) in Chicago, 24-28 August 2016.
Presentations include data evaluating MF59®-adjuvanted seasonal trivalent influenza vaccine in adults aged 65 years and older, MF59, quadrivalent inactivated influenza vaccine in people aged 5 years and older, and Rapivab® (peramivir injection), an antiviral drug. Seqirus will also be hosting "Dissecting the Influenza Challenge: Perspectives on Prevention and Management," a symposium led by:
Symposium Chair – Dr. Arnold Monto, MD, Professor, Epidemiology, University of Michigan
Symposium Faculty – Dr. Nelson Lee, MD, Head and Professor of Infectious Diseases, The Chinese University of Hong Kong, Honorary Consultant of the Hospital Authority of Hong Kong; Chairman of Infectious Diseases Board
Symposium Faculty – Dr. Paul Van Buynder, MBBS, MPH, Public Health Physician, Gold Coast Health Service
"The wealth of scientific knowledge presented at this year's Options IX conference underscores our commitment to the prevention and control of seasonal influenza," said Russell Basser, MD, Senior Vice President, Research & Development, Seqirus. "Seqirus is proud to offer one of the broadest portfolios of influenza vaccines this season, delivering on our promise to help improve public health around the world."
Data being presented across areas of focus for Seqirus include:
MF59-Adjuvanted Seasonal Trivalent Influenza Vaccine: Pooled Analysis of Safety in Adults 65 Years of Age or Older (Abstract # P-368, 26 August, 7:00 am – 7:30 pm CDT)
Heterologous Antibody Responses to MF59-Adjuvanted A/H5n1 Pandemic Vaccine in Adults, Pediatric and Elderly Populations (Abstract # P-363, 26 August, 7:00 am – 7:30 pm CDT)
Antibody Responses Against Antigenically Drifted Strains of FLUAD, a Seasonal MF59-Adjuvanted Trivalent Influenza Vaccine in Older Adults (Abstract # P-360, 26 August, 7:00 am – 7:30 pm CDT)
Health Economics for Seasonal Influenza Vaccination of Older Adults in Italy (Abstract # P-372, 26 August, 7:00 am – 7:30 pm CDT)
Randomized Trial to Compare Immunogenicity and Safety of Seqirus Quadrivalent Inactivated Influenza Vaccine with a US-Licensed Quadrivalent Influenza Vaccine in Children 5 to 17 Years of Age (Abstract # P-286, 26 August, 7:00 am – 7:30 pm CDT)
Randomized Trial to Compare Immunogenicity and Safety of Seqirus Quadrivalent Inactivated Influenza Vaccine with Two Trivalent Influenza Vaccine Comparators in Adults Aged 18 Years and Above (Abstract # P-498 Number, 26 August, 7:00 am – 7:30 pm CDT)
Peramivir susceptibility of Influenza A and B Neuraminidase Variants Selected Under Pressure with Neuraminidase Inhibitors (Abstract # O-6, 25 August, 12:15 – 12:30 pm CDT)
For a complete list of abstracts please visit: www.2016.isirv.org
Options IX is the largest international conference exclusively devoted to influenza prevention, control and treatment and is led by the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV).
About Seasonal Influenza
Influenza is a common, highly contagious infectious disease that can cause severe illness and life-threatening complications in many people. Because transmission to others may occur one day before symptoms develop and up to five to seven days after becoming sick, the disease can be easily transmitted to others. Influenza can lead to clinical symptoms varying from mild to moderate respiratory illness to severe complications, hospitalization and in some cases death. On average, more than 200,000 people are hospitalized due to influenza-related complications in the US each year.
Seqirus is the new global company created in July 2015 from the combined strength and expertise of bioCSL Inc. and the influenza vaccines business formerly owned by Novartis AG. As the second largest influenza vaccine provider in the world, Seqirus is driven by the promise it shares with parent company, CSL Limited, to provide medicines that help to protect and save lives.
Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally, with extensive research and production expertise and manufacturing plants in the US, Europe and Australia and a commercial presence in 20 countries.
Seqirus is part of CSL Limited (ASX:CSL), headquartered in Melbourne, Australia. The CSL Group of companies employs more than 16,000 people with operations in more than 30 countries.
For more information visit www.seqirus.com and www.csl.com.
Last updated on: 27/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.